Poseida Therapeutics: A Strong Buy on Innovative Gene Therapy Advancements and Strategic Focus

William Blair analyst Sami Corwin has maintained their bullish stance on PSTX stock, giving a Buy rating on April 12.

Sami Corwin has given his Buy rating due to a combination of factors including Poseida Therapeutics’ recent showcasing of its gene editing and nonviral delivery platforms, alongside promising updates on its gene therapy pipeline. The decision to prioritize the development of gene therapies for hemophilia A and hereditary angioedema, while shifting away from earlier-stage programs, indicates a focused strategy that optimizes resources toward more advanced candidates. Corwin recognizes the preclinical data from these programs and the innovative technologies like site-specific super PiggyBac and next-gen lipid nanoparticle (LNP) development platforms as strong indicators of the company’s potential.

Furthermore, Poseida’s strategic move towards a fully nonviral delivery platform using proprietary LNPs is seen as a decision that may offer scalability and greater control over therapy dosing. This technology’s potential to reduce hepatotoxicity and improve delivery to target cells, as well as the possibility of targeting tissues beyond the liver, presents a significant advancement in genetic medicine. Corwin also notes the current undervaluation of Poseida’s in vivo platform by the market, suggesting room for growth and future business development opportunities. The anticipation of preclinical updates and the progression of other key candidates in Poseida’s pipeline reinforce the Buy rating, projecting confidence in the company’s near-term value drivers.

In another report released on April 12, BTIG also assigned a Buy rating to the stock with a $12.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Poseida Therapeutics (PSTX) Company Description:

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumors.